ArticleThe journal of liquid biopsy2026
Web-based application of integrated clinico-genomic prognostic nomograms in metastatic castration-resistant prostate cancer.
Article in The journal of liquid biopsy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Survival in metastatic castration-resistant prostate cancer (mCRPC) is heterogeneous, and current prognostic models rely on clinical and non-tumor-specific laboratory variables. Plasma copy number alterations (CNAs) provide a blood-based measure of tumor biology for integrated clinico-genomic survival prediction in mCRPC. Methods: Plasma CNAs with prognostic significance were combined into a composite genomic prognostic score (CGPS) which was validated across three independent mCRPC cohorts (n = 561) for seven CNAs with gain/amplification in AR, MYC, and PIK3CA and loss/deletion in NKX3.1, TMPRSS2, TP53, ZBTB16. Multivariable Cox models with contemporary clinical prognostic factors alone, CGPS alone, and an integrated clinico-genomic model were built to estimate 24 and 36-month survivals. Model performances were assessed using the area under the curve (AUC) and freely accessible web-based applications were developed. Results: CGPS estimates across independent mCRPC cohorts showed high concordance with Pearson correlation coefficients of 0.86-0.97 for cross cohort comparisons. Time-dependent AUC values for the integrated clinico-genomic model at 24 and 36 months were 0.79 and 0.77, respectively, compared with 0.65 and 0.71 for using contemporary clinical factors alone and 0.74 and 0.69 for using CGPS alone. C-index was 0.73 for the integrated model compared with 0.70 for CGPS alone and 0.63 for clinical factors alone. The web application incorporates PSA, ALP, LDH, and CGPS and returns individualized survival probability estimates at 24 and 36 months. Conclusion: An integrated blood-based clinico-genomic prognostic model deployed as an open-access web application enables individualized survival estimation in mCRPC. This interactive tool could support prospective plasma CNA-based risk stratification in mCRPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.